Dipeptidyl peptidase-IV (DPP-IV) (EC 3.4.14.5) is а member of the broad class of hydrolytic enzymes which is responsible for degradation of the incretin peptide hormones regulating blood glucose levels. In this article we review the literature on natural and synthetic DPP-IV inhibitors, focusing their chemical structure and mechanism of action. Further, physico-chemical, pharmacokinetic and toxicological properties of DPP-IV inhibitors are calculated and compared. On the basis of literature data we selected the DPP-IV inhibitors with IC50 values below 1 nM and discussed their possible application in therapy of type 2 diabetes mellitus.

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568026615666150619142731DOI Listing

Publication Analysis

Top Keywords

dpp-iv inhibitors
12
dipeptidyl peptidase-iv
8
overview dipeptidyl
4
inhibitors
4
peptidase-iv inhibitors
4
inhibitors linking
4
linking structure
4
structure physico-chemical
4
physico-chemical properties
4
properties sar
4

Similar Publications

Linagliptin: A comprehensive profile.

Profiles Drug Subst Excip Relat Methodol

January 2025

Department of Chemistry, School of Sciences and Engineering, The American University in Cairo, AUC Avenue, New Cairo, Egypt. Electronic address:

Linagliptin (LINA) is the first dipeptidyl peptidase IV (DPP-IV) inhibitor that could be administered orally to control hyperglycemia. It is indicated for controlling adult blood sugar levels that are diagnosed with diabetes mellitus type II. The current chapter provides a complete review of LINA including nomenclature, physiochemical characteristics, synthesis, and thermal analysis.

View Article and Find Full Text PDF

Objective: To describe the outcomes of a partnership between a drug plan and pharmacists to switch patients from brand name dipeptidyl-peptidase-4 inhibitors to the generic alogliptin.

Study Design: Single-center, retrospective chart review.

Methods: Clinical pharmacists contacted patients with primary care providers within the health system affiliated with the drug plan to facilitate the switch.

View Article and Find Full Text PDF

Objectives: To assess the association between sodium-glucose co-transporter-2 inhibitor (SGLT-2i) use and the risk of incident dementia compared with dipeptidyl peptidase-4 inhibitors (DPP-4i) use among individuals with type 2 diabetes.

Design: A population-based retrospective cohort study.

Setting: The Clinical Practice Research Datalink (CPRD) Aurum database from the UK.

View Article and Find Full Text PDF

Orally administered prednisolone decreases plasma arginine vasopressin and serum copeptin concentrations in healthy dogs.

J Vet Intern Med

January 2025

Department of Small Animal Clinical Sciences, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.

Background: The pathophysiology of polyuria and polydipsia secondary to exogenous glucocorticoid excess is incompletely understood.

Objective: Investigate plasma AVP (pAVP) and serum CoP (sCoP) concentrations in healthy dogs before, during, and after abrupt discontinuation of a long-term course of orally administered prednisolone.

Animals: Eight healthy neutered young adult research Beagles.

View Article and Find Full Text PDF

Use of glucagon-like peptide-1 receptor agonists in people with history of acute pancreatitis: TriNetX analysis.

Diabetes Metab

January 2025

Professor of Medicine, Division of Endocrinology and Metabolism, Jacobs School of Medicine, University at Buffalo, Buffalo, NY, USA. Electronic address:

Introduction: . Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are used in subjects with type 2 diabetes (T2D) and obesity. However, concerns over their association with acute pancreatitis (AP) have emerged.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!